David Brown, MD
Ophthalmology · Houston, TXNPI 1548368509
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $458,575 of the $513,675 with a category attached, or 89.3%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.6%. 2025 is the largest year on record at $159,752, 5.4 times the $29,796 reported in 2019. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $1136.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optos PLC$95K
- Topcon Healthcare, Inc.$95K
- Regeneron$94K
- Novartis Pharma AG$59K
- Celltrion, Inc.$31K
- Novartis$31K
- plus $109K from 29 others
Across 3,903 payments — averaging $13,119 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$26.3M
- Genentech, Inc.$13M
- Roche TCRC, Inc.$4.8M
- Regeneron$3.2M
- Bayer$1.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$987K
- plus $1.8M from 18 others
What the payments were for
- Consulting fees$458,57589%
- Speaking & faculty fees$20,3324%
- Travel & lodging$18,6414%
- Food & beverage$13,5213%
- Gifts$2,5280%
- Entertainment$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optos PLC | 20 | $95,480 |
| Topcon Healthcare, Inc. | 11 | $95,063 |
| Regeneron | 59 | $93,969 |
| Novartis Pharma AG | 15 | $58,502 |
| Celltrion, Inc. | 4 | $31,320 |
| Novartis | 16 | $30,589 |
| Apellis Pharmaceuticals, Inc. | 51 | $26,356 |
| Boehringer Ingelheim International GmbH | 12 | $10,810 |
| Ocular Therapeutix, Inc. | 17 | $10,769 |
| Regeneron Healthcare Solutions, Inc. | 62 | $10,618 |
| AstraZeneca | 2 | $7,475 |
| Kowa Research Institute, Inc. | 4 | $6,000 |
| AbbVie(2 entities) | 38 | $5,847 |
| Boehringer Ingelheim | 9 | $5,811 |
| Biogen | 30 | $4,282 |
| Samsung Bioepis Co., Ltd. | 1 | $3,900 |
| Genentech USA, Inc. | 26 | $3,475 |
| Carl Zeiss Meditec, Inc. | 1 | $2,528 |
| Eyepoint US, Inc. | 4 | $2,321 |
| Apotex Inc. | 1 | $2,000 |
| Harrow Eye, LLC | 4 | $1,667 |
| Optos, Inc. | 2 | $1,042 |
| Amgen(2 entities) | 2 | $946 |
| Astellas Pharma US Inc | 23 | $647 |
| Carl Zeiss Meditec USA, Inc. | 9 | $553 |
| Heidelberg Engineering, Inc. | 4 | $398 |
| Alcon | 3 | $251 |
| Coherus Oncology, Inc. | 3 | $201 |
| Johnson & Johnson(2 entities) | 11 | $200 |
| Mckesson Specialty Care Distribution, LLC | 1 | $182 |
| Cardinal Health 108 LLC | 1 | $136 |
| US Oncology Corporate, Inc. | 2 | $135 |
| ASD Specialty Healthcare, LLC | 1 | $134 |
| Genentech, Inc. | 2 | $40 |
| Medinc Of Texas | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$91,301
- BLZ_BEOVU_OPHTHALMOLOGY$33,056
- BEOVU$21,500
- EYLEA HD$12,945
- Syfovre$12,082
- PANORAMIC OPHTHALMOSCOPE$11,250
- RTH258A_BEOVU_OPHTHALMOLOGY$8,725
- DEXTENZA$6,727
- BUPARLISIB$5,497
- P200TxE$5,125
- PLEX Elite 9000$2,528
- Lucentis$2,355
- EYP-1901$2,213
- AFLIVU$2,000
- IHEEZO$1,645
- P200DTx$1,500
- P200T$1,500
- P200TE$1,500
- TRIESENCE$1,400
- Spectralis$308
How this compares
$513,675 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 66 | $3,064 |
| Bromfenac Sodium | 13 | $2,349 |
| Ketorolac Tromethamine | 60 | $1,301 |
| Atropine Sulfate | 14 | $407 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $306 |
| Latanoprost | 27 | $252 |
| Brimonidine Tartrate | 14 | $237 |
| Timolol Maleate | 25 | $198 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $174 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
- Rahul PanditHouston$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.